United Kingdom
The Netherlands, Switzerland, Austria, Italy, Sweden, Denmark, France, Poland
Israel, Greece

The University of Manchester

The University of Manchester (UMAN) – The United Kingdom
The University of Manchester is the largest university campus in Europe and one of the leading research institutions in the United Kingdom.  UoM is currently ranked 3rd behind Oxford and Cambridge for research power. UoM has a strong credentials in PK-PD modeling.  The School of Translational Medicine has a strong focus on anti-infective research, clinical mycology, pharmacology, drug discovery and development of novel diagnostics/ biomarkers for infection.  UoM has developed novel models if infection and used these to further define and optimise anti-infective therapy.  There is a strong interest in antifungal drug resistance, combination chemotherapy and mathematical modelling.

Main tasks
UMAN will contribute to population PK analysis in WP3 and help in the design and analysis of the clinical trial.  UMAN will also conduct the in vivo PK-PD experiments and perform the mathematical modelling/ analyses for the MRSA combination studies in WP4.  Furthermore, UoM will contribute to modeling in other WP where specific expertise are indicated or required.

Previous experience
UMAN has state-of-the-art laboratory animal facilities along with the necessary infrastructure to conduct preclinical and clinical PK-PD
studies.  There is an existing expertise and demonstrated track record in using mice, rats and rabbits along with a number of in vitro PK-PD models.  A number of different biomarkers are used to measure antimicrobial effect.  There is extensive experience in population PK modelling, development of large linked PK-PD mathematical models and Monte Carlo simulation.  These techniques have been applied for optimisation of dosing for humans and investigation of clinical relevance of antimicrobial drug resistance  UoM receives funding from pharmaceutical industry, the National Institute of Health Research (NIHR, UK), National Institutes of Health (NIH, USA) and the Medical Research Council (MRC,UK).

Key personnel
William Hope (MBBS, PhD) was trained as an Infectious Diseases physician and Clinical Microbiologist. His research training focused on antimicrobial PK-PD with emphasis on antifungal agents.  His current work involves the optimisation of antimicrobial agents for both individuals and populations using in vivo-to-clinical bridging techniques. Dr Hope has an interest in population PK modelling, PK-PD mathematical modelling and Monte Carlo simulation.  He is currently secretary of Antifungal Susceptibility Testing subcommittee of EUCAST (European Committee on
Antimicrobial Susceptibility Testing) and is also leading the development of guidelines for treatment of Candida infections in pediatric patients.